BeiGene Debt to Equity Ratio 2014-2024 | ONC
Current and historical debt to equity ratio values for BeiGene (ONC) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. BeiGene debt/equity for the three months ending September 30, 2024 was 0.05.
| BeiGene Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-09-30 |
$2.40B |
$3.44B |
0.70 |
| 2024-06-30 |
$2.35B |
$3.37B |
0.70 |
| 2024-03-31 |
$2.31B |
$3.36B |
0.69 |
| 2023-12-31 |
$2.27B |
$3.54B |
0.64 |
| 2023-09-30 |
$1.76B |
$3.76B |
0.47 |
| 2023-06-30 |
$1.93B |
$3.80B |
0.51 |
| 2023-03-31 |
$1.80B |
$4.16B |
0.43 |
| 2022-12-31 |
$2.00B |
$4.38B |
0.46 |
| 2022-09-30 |
$2.07B |
$4.66B |
0.45 |
| 2022-06-30 |
$2.08B |
$5.30B |
0.39 |
| 2022-03-31 |
$2.14B |
$5.89B |
0.36 |
| 2021-12-31 |
$2.40B |
$6.13B |
0.39 |
| 2021-09-30 |
$1.93B |
$3.36B |
0.58 |
| 2021-06-30 |
$1.92B |
$3.61B |
0.53 |
| 2021-03-31 |
$1.82B |
$4.00B |
0.45 |
| 2020-12-31 |
$1.73B |
$3.87B |
0.45 |
| 2020-09-30 |
$1.27B |
$4.30B |
0.30 |
| 2020-06-30 |
$1.36B |
$2.55B |
0.53 |
| 2020-03-31 |
$1.24B |
$2.83B |
0.44 |
| 2019-12-31 |
$0.63B |
$0.98B |
0.65 |
| 2019-09-30 |
$0.59B |
$1.29B |
0.45 |
| 2019-06-30 |
$0.58B |
$1.57B |
0.37 |
| 2019-03-31 |
$0.55B |
$1.62B |
0.34 |
| 2018-12-31 |
$0.50B |
$1.75B |
0.28 |
| 2018-09-30 |
$0.43B |
$1.98B |
0.21 |
| 2018-06-30 |
$0.43B |
$1.23B |
0.35 |
| 2018-03-31 |
$0.35B |
$1.36B |
0.26 |
| 2017-12-31 |
$0.36B |
$0.68B |
0.53 |
| 2017-09-30 |
$0.29B |
$0.76B |
0.37 |
| 2017-06-30 |
$0.20B |
$0.27B |
0.75 |
| 2017-03-31 |
$0.07B |
$0.31B |
0.22 |
| 2016-12-31 |
$0.05B |
$0.35B |
0.15 |
| 2016-09-30 |
$0.05B |
$0.19B |
0.25 |
| 2016-06-30 |
$0.03B |
$0.22B |
0.14 |
| 2016-03-31 |
$0.02B |
$0.24B |
0.09 |
| 2015-12-31 |
$0.04B |
$0.07B |
0.57 |
| 2015-09-30 |
$0.04B |
$0.10B |
0.36 |
| 2015-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2015-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2014-12-31 |
$0.11B |
$-0.05B |
-2.01 |
| 2013-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
